Charles River Laboratories Intl. Inc (CRL) Stock Price Today
Aura AI Summary
Key Stats
- $10.81BMarket Cap
- -Volume
- HealthSector
- $233.6052W High
- $145.5752W Low
- -Typical Hold Time
- $13.67BEnterprise Value
- -Div Yield
- -Trading Activity
Track Charles River Laboratories Intl. Inc (CRL) stock price today on Pluang, updated in real time with live charts and market data. Over the past 52 weeks, Charles River Laboratories Intl. Inc has traded between a low of $145.57 and a high of $233.6, highlighting its annual price range. Buy and sell Charles River Laboratories Intl. Inc shares on Pluang with fractional shares and real-time market data — safe and OJK-regulated.
About Charles River Laboratories Intl. Inc
Charles River Laboratories was founded in 1947 and is a leading provider of drug discovery and development services. The company's research model & services segment is the leading provider of animal models for laboratory testing, which breeds and delivers animal research models with specific genetic characteristics for preclinical studies around the world. The discovery & safety assessment segment includes services required to take a drug through the early development process, including discovery services. The manufacturing support segment includes microbial solutions, which provides in vitro (non-animal) testing products, biologics testing services, and avian vaccine services.
Most Recent News
Urology devices market to double to $80B by 2035, driven by robotic surgery and kidney disease treatment.
The global urology devices market, valued at $39.23 billion in 2025, is projected to grow at a CAGR of 7.35% to reach $80 billion by 2035. Growth is fueled by rising demand for robotic-assisted surgeries, kidney disease management, and minimally inva...
Quantum photonics market to hit $14.12B by 2035, driven by quantum computing and secure communication tech.
The global quantum photonics market, valued at $0.77 billion in 2025, is projected to grow at a CAGR of 33.79% to reach $14.12 billion by 2035. Growth is fueled by the commercialization of quantum computing, secure quantum communication networks, and...
Positive Phase 2a data for Namodenoson in advanced pancreatic cancer accepted for presentation at ESMO 2026.
Can-Fite BioPharma announced that positive Phase 2a study results of Namodenoson, a drug for advanced pancreatic ductal adenocarcinoma, have been accepted for presentation at the ESMO Congress 2026. The study showed durable disease stabilization and ...
People also bought
Frequently Asked Questions
All investments involve risks and the possibility of a loss in investment value. Past performance is not indicative of future results. Historical performance, expected returns, and probability projections are provided for informational and illustrative purposes only.